Amedisys Inc Releases First-Quarter Supplemental Slides
TipRanks (Wed, 24-Apr 5:03 PM ET)
Amedisys Non-GAAP EPS of $1.03 beats by $0.02, revenue of $571.41M beats by $2.16M
Seeking Alpha News (Wed, 24-Apr 4:55 PM ET)
Amedisys Reports First Quarter 2024 Financial Results
Globe Newswire (Wed, 24-Apr 4:45 PM ET)
DOJ case against UnitedHealth could take years to resolve, says BoA
Seeking Alpha News (Fri, 19-Apr 4:12 PM ET)
Amedisys Reports Fourth Quarter and Year-End 2023 Financial Results
Globe Newswire (Wed, 21-Feb 4:30 PM ET)
Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis
Globe Newswire (Thu, 8-Feb 7:30 AM ET)
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Amedisys trades on the NASDAQ stock market under the symbol AMED.
As of April 24, 2024, AMED stock price declined to $91.05 with 79,275 million shares trading.
AMED has a beta of 0.23, meaning it tends to be less sensitive to market movements. AMED has a correlation of 0.03 to the broad based SPY ETF.
AMED has a market cap of $2.97 billion. This is considered a Mid Cap stock.
Last quarter Amedisys reported $571 million in Revenue and $.94 earnings per share. This beat revenue expectation by $3 million and missed earnings estimates by -$.09.
In the last 3 years, AMED stock traded as high as $292.97 and as low as $69.37.
The top ETF exchange traded funds that AMED belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
AMED has underperformed the market in the last year with a return of +15.6%, while the SPY ETF gained +24.2%. In the last 3 month period, AMED fell short of the market, returning -3.9%, while SPY returned +4.6%. However, in the most recent 2 weeks AMED has outperformed the stock market by returning -1.8%, while SPY returned -2.7%.
AMED support price is $90.59 and resistance is $91.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMED stock will trade within this expected range on the day.